# Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer

> **NCT06143553** · PHASE3 · RECRUITING · sponsor: **Shanghai Yizhong Pharmaceutical Co., Ltd.** · enrollment: 168 (estimated)

## Conditions studied

- Metastatic Breast Cancer (MBC)

## Interventions

- **DRUG:** Paclitaxel Polymeric Micelles for Injection
- **DRUG:** Eribulin Mesilate injection
- **DRUG:** Capecitabine Tablets
- **DRUG:** Gemcitabine Hydrochloride for Injection
- **DRUG:** Vinorelbine Tartrate Injection
- **DRUG:** Paclitaxel (albumin-bound)

## Key facts

- **NCT ID:** NCT06143553
- **Lead sponsor:** Shanghai Yizhong Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-25
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2024-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06143553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06143553, "Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06143553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*